A possible combination of the new approved therapeutic strategies of Her2-negative and Her2-positive advanced esophagogastric adenocarcinoma treatment in Europe is provided in Figure 1. This evidence concerns the gene ERBB2 and gastroesophageal junction adenocarcinoma.